Cargando…
The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial
AIM: The role of surgical castration and rosuvastatin treatment on lipid profile and lipid metabolism related markers was evaluated for their prognostic significance in metastatic prostate cancer (mPC) patients. METHODS: A total of 84 newly diagnosed castrated mPC patients treated with castration we...
Autores principales: | Karkeet, Riham M., Zekri, Abdelrahman N., Sayed-Ahmed, Mohamed M., Sherif, Ghada M., Salem, Salem E., Abdelbary, Ahmed, Fouad, Mariam A., Saad, Sherif Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731457/ https://www.ncbi.nlm.nih.gov/pubmed/36480560 http://dx.doi.org/10.1371/journal.pone.0278282 |
Ejemplares similares
-
Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity
por: Ludolph, Barbara, et al.
Publicado: (2007) -
Predictive Modeling
of HMG-CoA Reductase Inhibitory
Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023) -
Pleiotropic effects of the HMG-CoA reductase inhibitors
por: Mihos, Christos G, et al.
Publicado: (2011) -
The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
por: Gelosa, Paolo, et al.
Publicado: (2007) -
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo
por: Noël, Martin, et al.
Publicado: (2004)